FDA Clears Investigational New Drug Application for Influenza Antiviral
Via Nova Therapeutics’ VNT-101 is an Influenza A nucleoprotein inhibitor.
Via Nova Therapeutics announced that FDA has cleared its investigational new drug application for VNT-101.
The new therapy is a novel investigational small molecule that is described as an Influenza A nucleoprotein inhibitor. In a press release, Via Nova states that VNT-101 demonstrated activity in vitro against a variety of flu strains, including seasonal influenza A and avian influenza H5N1 and H7N9.
In the press release, Via Nova Therapeutics Ceo and co-founder Don Ganem, M.D., said, “We look forward to evaluating VNT-101 in the clinic. This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."
Source
(Sept. 21, 2023); PR Newswire; Via Nova Therapeutics Announces FDA Clearance of Investigational New Drug Application for VNT-101, A Novel Direct-Acting Antiviral Against Influenza A Virus; https://www.prnewswire.com/news-releases/via-nova-therapeutics-announces-fda-clearance-of-investigational-new-drug-ind-application-for-vnt-101-a-novel-direct-acting-antiviral-against-influenza-a-virus-301934192.html?tc=eml_cleartime
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
